Julie Brown Buys 7 Shares of GSK (LON:GSK) Stock

GSK plc (LON:GSK) insider Julie Brown purchased 7 shares of GSK stock in a transaction that occurred on Tuesday, May 12th. The shares were bought at an average cost of GBX 1,866 per share, with a total value of £130.62.

Julie Brown also recently made the following trade(s):

• On Monday, April 13th, Julie Brown purchased 5 shares of GSK stock. The shares were purchased at an average cost of GBX 2,171 per share, for a total transaction of £108.55.

GSK Stock Performance

LON GSK traded down GBX 11 during trading on Thursday, reaching GBX 1,875. 41,102,586 shares of the company’s stock were exchanged, compared to its average volume of 9,575,882. The business has a 50 day moving average price of GBX 2,037.83 and a 200-day moving average price of GBX 1,938.72. GSK plc has a fifty-two week low of GBX 1,288.61 and a fifty-two week high of GBX 2,282. The stock has a market capitalization of £74.85 billion, a P/E ratio of 13.19, a PEG ratio of 1.24 and a beta of 0.30. The company has a debt-to-equity ratio of 106.74, a current ratio of 0.79 and a quick ratio of 0.73.

GSK (LON:GSK) last posted its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share (EPS) for the quarter. The company had revenue of GBX 762.90 billion during the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. Sell-side analysts forecast that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on GSK shares. UBS Group reaffirmed a “neutral” rating and issued a GBX 1,940 target price on shares of GSK in a research note on Friday, January 23rd. Shore Capital Group reaffirmed a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. Berenberg Bank reaffirmed a “hold” rating and set a GBX 2,000 price target on shares of GSK in a research report on Thursday, March 26th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 target price on shares of GSK in a report on Tuesday, April 14th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 1,900 price target on shares of GSK in a report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of GBX 2,034.29.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.